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Metformin is the most widely used antidiabetic drug because of its proven efﬁcacy and limited secondary effects. Interestingly,
recent studies have reported that metformin can block the growth of different tumor types. Here, we show that metformin exerts
antiproliferative effects on melanoma cells, whereas normal human melanocytes are resistant to these metformin-induced
effects. To better understand the basis of this antiproliferative effect of metformin in melanoma, we characterized the sequence
of events underlying metformin action. We showed that 24h metformin treatment induced a cell cycle arrest in G0/G1 phases,
while after 72h, melanoma cells underwent autophagy as demonstrated by electron microscopy, immunochemistry, and by
quantiﬁcationofthe autolysosome-associatedLC3 andBeclin1proteins. Inaddition,96hpost metformin treatment weobserved
robust apoptosis of melanoma cells. Interestingly, inhibition of autophagy by knocking down LC3 or ATG5 decreased the extent
of apoptosis, and suppressed the antiproliferative effect of metformin on melanoma cells, suggesting that apoptosis is a
consequence ofautophagy.Therelevance ofthese observationswereconﬁrmedinvivo,asweshowedthatmetformintreatment
impaired the melanoma tumor growth in mice, and induced autophagy and apoptosis markers. Taken together, our data suggest
that metformin has an important impact on melanoma growth, and may therefore be beneﬁcial in patients with melanoma.
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Cutaneous melanoma deriving from the transformation of
pigment-producing melanocytes is one of the most lethal
cancers among young adults. Its incidence has increased at a
dramatic rate during the last decades. Melanoma progression
is characterized by an initial radial growth phase, encom-
passing in situ and minimally invasive tumors. This phase is
followed by the development of vertical growth phase, which
has been postulated to be the ﬁrst point at which the tumor
gains metastatic ability. Indeed, melanoma has a high
capability of invasion and rapid metastasis to other organs.
The prognosis of metastatic melanoma is extremely pejora-
tive, as the various protocols of chemotherapy or immu-
notherapy have not shown, for the moment, real survival
beneﬁt.
1 In addition to active prevention and early detection of
melanomas,itappearsnecessarytodevelopnewapproaches
enabling the discovery of new molecular target candidates for
speciﬁc biotherapy treatment of this disease.
To this purpose, we have been interested in studying the
effect of the oral antidiabetic drug, metformin, on melanoma.
Metformin belongs to the family of biguanide and is the most
widely used antidiabetic drug in the world.
2 The effect of
metformin on glucose homeostasis has been explained
through reduced hepatic gluconeogenesis and increased
glucose uptake in skeletal muscles.
3,4 This drug has the
major clinical advantage of not inducing hypoglycemia and
being tolerated very well. It is associated with only very low
incidence of lactic acidosis (1/30000) predominantly in
patients with altered kidney or liver functions.
5 The mechan-
ism through which metformin reduces hepatic glucose
production requires LKB1, which controls the AMPK
(AMP-activated protein kinase)/mTOR (mammalian target of
rapamycin) pathway and neoglucogenic genes.
6
Metformin action on the AMPK/mTOR pathway leads to
reduced protein synthesis and cell proliferation. These
observations have given the impetus to numerous studies
on the role of metformin in the regulation of tumor cell
proliferation and apoptosis. Encouraging results emerged
from thesestudiesindicating thatmetformin canpotentiallybe
used as an efﬁcient anticancer drug in various neoplasms
such as prostate, breast, lung and pancreas cancers.
7,8
These results were conﬁrmed by retrospective epidemio-
logical studies that reported a decrease in cancer risk in
diabetic patients treated with metformin.
7,9 Importantly, a
recent work of Nakajima lab demonstrates that metformin
diminishes theformation of rectal aberrant cryptfoci,a marker
of colorectal cancer, in non-diabetic patients.
10 Despite
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www.nature.com/cddiscompelling evidence of a role of metformin as an anticancer
drug, its mode of action in cancer remains unelucidated. In a
few studies, metformin induces apoptosis in cancer,
11–13 and
in one study performed on colon cancer, metformin triggers
autophagy.
14 Undoubtedly, in cancer there are multiple
functional relationship reported between the apoptosis and
autophagy,andtheseprocessesseparatelyor/andjointlyseal
the fate of the cell.
15 Thus, apoptosis or/and autophagy are
interesting mechanisms to induce cancer cell death.
In this work, we wished to study the effect of metformin on
melanoma cell viability, and to further investigate the
molecular mechanisms by which metformin exerts its action
on melanoma cells.
Results
Metformin exerts a deleterious effect on melanoma cell
viability. Metformin has been shown to affect the
proliferation of several human cancer cell lines derived
from the prostate, colon, gliomas and breast, in the 1–10mM
range. To investigate the effect of metformin on melanoma
cells, we treated different human melanoma cell lines (A375,
WM9, SKMel28 and G361) with metformin, and monitored
cell number. As shown in Figure 1a, 72h exposure of cells to
various concentrations of metformin led to dose-dependent
decrease in cell number. In contrast, human melanocytes
were resistant to metformin treatment. In addition, metformin
induced dose-dependent decrease in cell number of two
melanoma cell samples freshly isolated from patient tumors
(Figure 1b). Time-course experiments showed a rapid effect
of 10mM metformin, with an almost immediate and important
decrease of cell number in comparison to phosphate-
buffered saline (PBS) control (Figure 1c).
Metformin induces autophagy. To elucidate whether
AMPK activation is modulated in response to metformin,
we studied the phosphorylation at Thr-172 of AMPK-a
(AMPK T172) as a read-out of its activation state.
Figure 2a shows that metformin induced a dose-dependent
increase of AMPK T172 phosphorylation in A375 melanoma
cell lines. We next examined the effect of metformin on the
activity of mTOR, a downstream effector of AMPK. We
observed a net decrease in the phosphorylation status of
mTOR and S6 Ribosomal protein, suggesting a blockade of
the mTOR pathway. As the mTOR pathway is a central
regulator of multiple cellular responses to nutrient and growth
factor signaling, including autophagy, we analyzed whether
metformin might induce characteristic hallmarks of autophagy.
During autophagy, LC3-I is converted to LC3-II through the
ATG4-dependent insertion of a phosphoethanolamine moiety
and recruited into the membrane of the forming phagophore, a
double membrane required for the recycling of protein
aggregates and organelles.
16 Increased LC3 expression was
detected for two doses of metformin. At the same
concentrations, metformin also enhanced the expression level
of Beclin 1, a protein required for the initiation of the formation of
the autophagosome in autophagy.
These data collectively strongly argue the induction
of macroautophagy by metformin. Accordingly, electron
microscopy images of A375 cells treated for 72h with
metformin showed typical images of autophagy including
accumulation of numerous vesicles with distinct double
membrane (Figure 2b). In addition, early autophagosomes
sequestering cytosol, mitochondrion, or endoplasmic reticu-
lum membranes were observed. By contrast, control
melanoma cells (PBS) showed no autophagic vacuoles.
Similar results were obtained with SKMel28 melanoma cells
(Supplementary Figure S2).
In addition, following transfection of melanoma cells with
RFP-LC3 construct, the formation of RFP puncta in cells
treated with metformin was observed, whereas the untreated
cells exhibited a diffuse distribution of red ﬂuorescence in the
cytoplasm and nucleus (Figure 2c).
The observation that metformin affected the lysosomal
compartment was further substantiated by the increase of
cathepsin B activity mediated by metformin at 72h in A375
and SKMel28 cells (Figure 2d). Importantly, increased
cathepsin B activity has been associated with the late steps
of autophagy.
17
Metformin induces cell death. To determine whether
autophagy mediated by metformin affects cell viability, we
analyzed the percentage of cell death, by staining with
propidium iodide (PI) in response to various metformin
concentrations in A375 melanoma cells. Metformin induced
a dose-dependent increase of cell death (Figure 3a). At a
10mM metformin concentration, B40% of the cells were
dead. This result was comparable to that obtained with the
proapoptotic effector, staurosporine.
Previous studies have demonstrated that coregulation of
apoptosis and autophagy can participate in mammalian cell
death. To analyze the relationships between apoptosis and
autophagy in melanoma cell death, we treated A375
melanoma cells for different times with 5 and 10mM
metformin. To monitor apoptosis, we evaluated both the
cleavage of DNA repair enzyme poly(ADP-ribose) polymer-
ase (PARP; Figure 3b) and the activation of caspase 3
(Figure 3c).Inparallel, we determined autophagy induction by
measuring the expression of LC3-b, Beclin 1 and ATG5. As
shown in Figure 3b, PARP cleavage was signiﬁcantly
increased after 72h of treatment with 5 or 10mM metformin.
Atthesametime,aclearactivationofcaspase3wasdetected
(Figure 3c). In the same period of time, we also detected an
increased expression of three proteins involved in autophagy
process such as LC3, Beclin1 and ATG5. The apoptosis
inductor staurosporine was found to induce apoptosis but not
autophagy. These results were conﬁrmed by quantiﬁcation of
western blots using a Fuji Film, Multi Gauge Ver 3.0 software
(Fuji Film, Tokyo, Japan) (Figure 3b, lower part). Taken
together, these results indicate that metformin induces a
concomitant induction of autophagy and apoptosis processes
in melanoma cells, both of which are involved in cell death. To
identify the event sequence of autophagy and apoptosis, we
have performed another kinetics of 6h intervals. Supplemen-
tary Figure S3 clearly shows that the increase of expression
and the conversion of LC3 precede the cleavage of PARP,
suggesting that the autophagy is set up before apoptosis.
In an attempt to identify the contribution of autophagy and
apoptosis or a switch between the two processes to induce
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Cell Death and Diseasecell death,we inhibitedautophagyand apoptosisusingLC3 or
ATG5 small interfering RNA (siRNA) and pan caspase
inhibitor Q-VD-OPH or caspase 3 siRNA, respectively. LC3
siRNA,whichdrasticallyreducedtheexpressionoftheprotein
(Figure 4a), prevented PARP cleavage (Figure 4a) and cell
death induced by metformin (Figure 4b). The apoptosis
inhibitor, Q-VD-OPH was capable of inhibiting PARP
cleavage and cell death induced by metformin. In contrast,
Figure 1 Metforminrepressesmelanomacellproliferation(a)PrimaryhumanmelanocytesandmelanomacelllinesA375,SKMel28,WM9andG361weretreatedwith
indicated concentrations of metformin. After 72h, viable cells were counted using trypan blue dye exclusion method. (b) Human melanoma cells freshly isolated from tumor
were stimulated for 72h with indicated concentrations of metformin. Viability of the cells was estimated by trypan blue staining. (c) A375 and SKMel28 were treated with PBS
and10mMmetforminduringdifferenttimes,andcellviabilitywasdeterminedbytrypanbluedyeexclusionassay.Foreachexperiment,cellnumberisexpressedinpercentof
control (100%). Data are mean±S.D. of three independent experiments performed in triplicate. Signiﬁcantly different from the corresponding control *Po0.05; **Po0.01;
***Po0.001
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Cell Death and DiseaseFigure 2 Metformin triggersautophagyin melanomacells.(a) A375 melanomacells weretreatedwith indicatedconcentrationsof metformin for 72h. Cell lysateswere
separatedbySDS-PAGEandanalysedbywesternblotusingtheindicatedantibody.HSP60andactinwereusedasloadingcontrol.Onerepresentativeexperimentofthreeis
shown. (b) Electron microscopy images presenting ultrastructure in representative control (PBS) and 10mM metformin-treated melanoma cells for 72h. Arrowheads,
autophagosomes.Nu,nucleus;M,mitochondria.(c)Representativeconfocalmicroscopyimagesof RFP-LC3stainingin melanomacellsexpressingRFP-LC3andstimulated
with or without metformin. In parallel (right panel), number of cells with RFP-LC3 dots were scored on 50 transfected cells. (d) Melanoma A375 and SKMel28 cells were
incubated without or with metformin for 72h, and cathepsin B activity was evaluated in the presence or absenceof CA-074Me. Results are expressed as arbitrary units(A.U.)
per mg of proteins. Data are mean±S.D. of representative experiment performed in triplicate. Signiﬁcantly different from the corresponding control ***Po0.001
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Cell Death and DiseaseQ-VD-OPH failed to impair LC3-II expression mediated by
metformin. As expected, combination of both LC3 siRNA and
Q-VD-OPH abolished autophagy, apoptosis and cell death
triggered by metformin. Similar results were found with ATG5
and caspase 3 siRNA (Supplementary Figure S4).
The anti-melanoma effect of metformin is partially
mediated by AMPK. The anticancer effects of metformin
have been essentially attributed to its ability to activate the
AMPK pathway. To evaluate the function of AMPK in the
effects of metformin, we knockdown both a1 and a2 catalytic
subunits of AMPK with previously validated siRNAs.
18 As
shown in Figures 5a and b, inhibition of a1 and a2 AMPK
subunits partially prevented cell death, and PARP cleavage
induced by 5 and 10mM metformin. Further, AMPK siRNA
inhibited partially LC3 cleavage at 5mM metformin but not at
10mM metformin. These observations suggest that
metformin mediates its anti-melanoma effects via both
AMPK-dependent and -independent pathways.
Metformin inhibits melanoma tumor development in
mice. Finally, to assess a potential antineoplastic effect of
metformin in vivo, A375 melanoma cells (2.5 10
6) were
injected subcutaneously in 6-week-old female athymic nude
mice and treated 5 days later by injection of vehicle or
metformin (2mg/mouse/day) over a period of 3 weeks.
Untreated control mice rapidly developed visible tumors, and
dramatic tumor growth was observed throughout the course
of the study (Figure 6a). In contrast, treatment of mice with
metformin markedly attenuated the ability of cells to develop
Figure 3 Metformin induces melanoma cell death. (a) A375 melanoma cells were treated with indicated concentrations of metformin for 96h. Cell death was
measuredby FACSanalysisofpropidiumiodideuptakeandresultswereexpressedas apercentageof effectivecelldeath.Staurosporine was usedasa controlof celldeath.
(b) A375 cells were incubated with metformin (5 or 10mM) for the indicated times or with staurosporine as control of cell death. Cell lysates were separated by SDS-PAGE
and analysed by western blot using the indicated antibody. HSP60 was used as loading control. One representative experiment of three is shown. Quantiﬁcation of western
blots were performed using Fuji Film, Multi Gauge. (c) A375 cells were incubated with metformin (5 or 10mM) for the indicated times or with staurosporine as control of cell
death. Caspase 3 activity was measured as indicated in Materials and Methods section. Signiﬁcantly different from the corresponding control *Po0.05; **Po0.01;
***Po0.001
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Cell Death and Diseasevisible tumors. Indeed, three of seven metformin-treated
mice had no measurable tumors. Moreover, tumors derived
from metformin-treated mice were consistently and
signiﬁcantly smaller than tumors from untreated control
mice (Figure 6b). These data clearly demonstrate that
metformin has anti-melanoma activity in vivo.
To conﬁrm the molecular mechanisms involved in the
antineoplastic effects of metformin in vivo, LC3 expression
was studied by immunoﬂuorescent staining on tumor sections
from mice treated with vehicle or metformin (Figure 6c, upper
part). Sections of tumors from mice treated with metformin
show a dramatic increase in LC3 staining compared with
sections of tumors from control mice injected with vehicle. In
addition, LC3 puncta, reminiscent of autophagosome forma-
tion in tumors of mice treated with metformin, were visualized.
To determine the level of apoptosis in the tumors of mice
treated with metformin, we performed a TUNEL assay on
section of different tumors. We observed an increase in
TUNEL-positive cells (green) in tumors sections from mice
treated with metformin compared with tumor sections from
mice treated with PBS.
In addition, to conﬁrm these results, we made western blot
from tumors of mice treated or not with metformin (Figure 6c,
lower part). As expected, we showed an increase in
expression and lipid conjugation of LC3b and cleavage of
PARP in tumors of mice treated with metformin in comparison
withcontrolmicetreatedwithPBS,suggestingthatautophagy
and apoptosis are also occurring in vivo.
Thus,thereductionoftumorvolumeandweightobservedin
metformin-treatedmiceseemstobe,atleastinpart, relatedto
the induction of autophagy and apoptosis.
Finally, we performed exactly the same experiment using a
syngeneic tumor model in which B16 melanoma cells were
injected in C57/Bl6 mice (Figure 6d). After 20 days of
metformin treatment (2mg/day/mouse), we observed a
signiﬁcant decrease in volume and weight of tumors for mice
treated with drug compared with control mice, thereby
conﬁrming the antineoplastic effect of metformin in mice.
Discussion
The discovery of new therapeutic compounds is a very
important challenge to treat advanced melanomas that are
resistant to existing therapies. To this purpose, using in vitro
and in vivo approaches, we demonstrate the potent anti-
melanoma activity of the antidiabetic metformin. Interestingly,
contrary to normal human melanocytes, drastic inhibition of
cell viability mediated by metformin is observed in four
different melanoma cell lines independent of the mutational
status or melanoma development stage, and in two primary
melanoma cell cultures freshly isolated from patients. These
ﬁndingsareconsistentwithresultsofWoodardetal.
19demon-
strating AMPK activators AICAR and metformin reduced the
proliferation of SKMel2 and SKMel28 melanoma cells.
Metformin action is mainly mediated by AMPK activation;
however, several recent reports indicate that some effects of
metformin in cancer cell lines could be mediated byan AMPK-
independent pathway.
20–23 In our model, AMPK silencing by
siRNA (Figure 5) or inhibition of AMPK activation by
pharmacological inhibitor (data not shown) inhibits only
partially the effect of metformin on melanoma cell death,
suggesting that the effects of this drug are mediated, at least
in part, through an AMPK-independent mechanism. In
addition, AMPK knockdown protects partially the cleavage
of PARP but fails to block the induction of LC3-b at 10mM
metformin. This result indicates that AMPK-dependent
component of anti-melanoma action of metformin could be
autophagy-independent. However, we cannot exclude that
the low residual AMPK expression is sufﬁcient to mediate
metformin effect on cell death. Noteworthy, treatment of
normal human melanocytes that express endogenous AMPK
with metformin did not affect cell viability (Figure 1a),
suggesting that metformin action is restrained to transformed
cell lines and likely reﬂects a tumor-speciﬁc regulation.
The AMPK/mTOR pathway is under the control of LKB1, a
serine-threonine kinase acting as a tumor suppressor.
A recent report demonstrates that oncogenic V600E B-RAF,
a common somatic mutation found in malignant melanoma
(50–70%), negatively regulates LKB1 to promote melanoma
cell proliferation.
24 In our model, LKB1 seems not to be
involved in metformin’s anti-melanoma effect as G361 cells,
which do not express LKB1, are also sensitive to the drug
(Figure 1a). Accordingly, overexpression of a dominant
negative form of LKB1 in melanoma cell lines did not prevent
metformin sensitivity (data not shown).
Another protein that can mediate metformin effect is the
tumor suppressor p53. Indeed, p53 functions as a transcrip-
tional regulator of genes involved in cell cycle arrest,
Figure 4 Autophagy is involved in apoptosis and antiproliferative effects of
metformin. A375 cells were transfected with either control or LC3b-speciﬁc siRNAs.
Cells were next preincubated with or without Q-VD-OPH (20mM) and exposed to
metformin (5 or 10mM) for 96h. (a) LC3-b expression and PARP cleavage were
analyzed by western blotting. HSP60 was used as a loading control. (b) FACS
analysis using propidium iodide was used to determine cell death. The results are
expressed as percentage of cell death compared with control. Data are expressed
as percentage of apoptotic cells and represent the mean±S.D. of six independent
experiments. Signiﬁcantly different from the corresponding control **Po0.01;
***Po0.001
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Cell Death and Diseaseautophagy and apoptosis pathways.
25 In addition, the AMPK-
p53 pathway may represent a cell cycle checkpoint in
response to energy limitation. AMPK has been shown to
phosphorylatep53 onSer-15toinduceG0/G1 phase arrest.
26
In our melanoma cell lines, p53 is not phosphorylated on
Ser-15 in response to metformin (data not shown). Further
melanoma cells harboring a mutated TP53 gene (SKMel28
cells) exhibited the same sensitivity to metformin as other
melanoma cell lines harboring wild-type p53 (Figure 1a),
indicating that p53 is not involved in metformin effects in our
cellular model.
Several recent reports have highlighted that metformin
induces cell cycle arrest of cancer cell lines.
7 We observed
here that the proportion of cells in G0/G1 was signiﬁcantly
increased in melanoma cells treated for 24h with metformin,
while apoptotic cells with fragmented DNA (sub G1) could not
be observed at 24h (Supplementary Figures S1a and b). Cell
cycle arrest in G0/G1 phase is associated at molecular level
with a dramatic reduction of cyclin D1 expression, a marked
increase in the expression of cyclin-dependent kinase
inhibitor p21Cip1/Waf1, and hypophosphorylation of pRb
(Supplementary Figure S1c).
However, the antiproliferative effect of metformin cannot be
exclusively explained by cell cycle arrest as a strong increase
in cell death was detected for longer time of drug treatment
(448h; Figure 3a). Autophagy is a catabolic process for the
degradation and recycling of macromolecules and organelles,
which is activated during stress conditions.
27,28 Autophagy is
initiated by the formation of double-membraned vesicles
called autophagosomes, which fuse with lysosomes to form
autophagolysosomes in which lysosomal hydrolases digest
the vesicle contents for recycling.
29 Autophagy is considered
as a survival mechanism induced in adverse conditions to
maintain cell integrity, but paradoxically, it is also involved in a
particular modeof deathcalled autophagiccell deathortype II
cell death.
30 In our study, several compelling evidences
indicate that metformin induces autophagy in melanoma cells
(Figure 2). This ﬁnding is particularly interesting as until now,
only one study has reported that metformin is able to induce
autophagy in colon cancer.
14 In this model and conversely to
the present study, p53 seems to be required for autophagy
after treatment with metformin. In agreement with this model,
we observed that blockage of autophagy by siRNAs directed
against LC3 and ATG5 (Figure 4a and Supplementary
Figure S4) or pharmacological inhibition of autophagy by
3-methyl adenine (data not shown) promotes melanoma cell
survival, suggesting that metformin does induce autophagic
cell death.
In addition, we observed that long-term treatment with
metformin induces apoptosis as monitored by caspase 3
Figure 5 AMP kinase partially mediates cell death induced by metformin in melanoma. A375 cells were transfected with combination of a1 and a2 AMPK siRNAs or
with control siRNA. The cellswere next treatedfor 96h with indicatedconcentration of metformin. (a) AMPKa subunit expression,LC3b expression and PARPcleavagewere
analyzed by western blotting. HSP60 was used as a loading control. Quantiﬁcation of western blots were performed using Fuji Film, Multi Gauge. (b) FACS analysis using
propidium iodide was used to determine cell death. The results are expressed as percentage of cell death compared with control. Data are expressed as percentage of
apoptotic cells and represent the mean±S.D. of three independent experiments. Signiﬁcantly different from the Si-control transfected cells
#Po0.05
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Cell Death and Diseaseactivation and PARP cleavage (Figures 3b and c). This result
is consistent with the fact that metformin has been previously
shown to promote apoptosis in several solid tumor cell lines.
7
To determine whether autophagy and apoptosis are linked
mechanisms, we performed several experiments following
inhibition ofapoptosisand/or autophagy.Inhibition ofcaspase
activation by Q-VD-OPH or caspase 3 siRNA did not dampen
LC3-II accumulation nor the melanoma cell death in response
to metformin (Figure 4 and Supplementary Figure S4),
suggesting that metformin-mediated apoptosis did not affect
induction of autophagy. In contrast, inhibition of metformin-
mediated autophagy prevented PARP cleavage, indicating
thatmetformin-mediated autophagy contributes to metformin-
induced apoptosis. This link between autophagy and apopto-
sis has been previously proposed for targeting melanoma
cells in response to cytosolic delivery of dsRNA.
31,32
To the best of our knowledge, this is the ﬁrst demonstration
that metformin through concomitant regulation of autophagy
and apoptosis favors elimination of cancer cells.
Beclin1 siRNAs were not able to block metformin-induced
autophagy and cell death (Supplementary Figure S4),
suggesting that metformin induced beclin1-independent
autophagy as previously described.
33–35 Several recent
reports described the central role of the complexes, Beclin1/
anti-apoptotic members of the Bcl-2 family in the cross-talk
between autophagy and apoptosis.
30 The fact that suppres-
sion of beclin1 did not modify autophagy and cell death
suggestedthatthisproteinwasnotinvolved inthemechanism
of cross-talk. Future studies in our lab will address the
mechanism(s) through which metformin signaling induces a
speciﬁc death in melanoma cells.
Finally, we have evaluated the anti-melanoma activity of
metformin in a mouse model of melanoma xenograft
(Figure 6). Importantly, we found that short-term administra-
tion (3 weeks) of metformin dramatically reduces the devel-
opment of melanoma tumors in mice. In addition, metformin
induces no apparent toxicity, as the body weight (data not
shown) and overall appearance of mice given a metformin
regimen were not different from those of controls. To
determine whether the molecular events observed in cell
lines were also found in mice, we performed immunohisto-
logical staining and TUNEL assay of mouse tumor sections.
Experiments showed an increase in LC3 puncta correspond-
ing to autophagosomes and an increase in TUNEL-positive
cells in the tumors of metformin-treated mice. These results
suggest that in vivo metformin induced autophagy and
apoptosis. To circumvent partial immunity deﬁciency found
in nude mice, we also performed the same experiment in a
syngeneic model using allograft of B16 melanoma cells in
C57Bl6 mice. We have previously checked that metformin
Figure 6 Effect of metformin on melanoma tumor growth in mice. Female immune-deﬁcient BALB/c nu/nu (nude) mice were inoculated subcutaneously with A375
melanoma cells (2.5 10
6), and after 5 days animals (n¼6 in each group) were treated with metformin (2mg/mice/day) or PBS over 3 weeks. (a) The growth tumor curves
weredeterminedbymeasuringthetumorvolume.(b)Micewereeuthanizedandtumorswereweighed.*Po0.05;**Po0.01.(c)Frozensectionsoftumorsfrommicetreated
with PBS or metformin were ﬁxed and stained using LC3-b (green) and DAPI (blue) or using TUNEL assay (green). Slides were examined with a Zeiss Axiophot ﬂuorescence
microscope. Representative sections are shown. The experiment was repeated on sections from four mice per condition. Images were treated and analyzed with ImageJ
softwarefor LC3 ﬂuorescence quantiﬁcationusingDAPIﬂuorescenceas internalcontrol. LC3expression and PARPcleavagewereanalyzedby westernblotting.HSP60was
usedasaloadingcontrol.(d)FemaleC57BL/6micewereinoculatedsubcutaneouslywithB16F10melanomamurinecells(2.5 10
5),andafter7daysanimals(n¼6ineach
group)weretreatedwithmetformin(2mg/mice/day)orPBSover3weeks.Micewereeuthanized.Thegrowthoftumorsweredeterminedbymeasuringthetumorvolume,and
tumors were weighed. Signiﬁcantly different from the corresponding control *Po0.05; **Po0.01
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Cell Death and Diseasedecreased viability of melanoma B16 cells in vitro (data not
shown). Also in this model, metformin diminished the volume
and weight of tumor of treated mice, conﬁrming the
antineoplastic effect of this compound in vivo.
In summary, we demonstrate for the ﬁrst time that
metformin inhibits melanoma tumor growth through an
autophagy-dependent mechanism. This ﬁnding brings new
clues to the understanding of metformin action in melanoma
cell death. Finally, taking into account the drastic effect of
metformin on melanoma cell growth and survival in mice, it
might be worth evaluating metformin treatment in patients
suffering from metastatic melanoma.
Materials and Methods
Reagents and antibodies. Metformin, staurosporine, phenylmethylsulfonyl
ﬂuoride, PI, 3-isobutyl-1-methylxanthine,hydrocortisone, insulin, phorbol-12myristate
13-acetate,MCDB153medium,sodiumﬂuoride,dimethylacetamide,Hoechst33258,
sodium orthovanadate, 4-(2-aminoethyl)-benzene-sulfonyl ﬂuoride, aprotinin and
leupeptin were purchased from Sigma-Aldrich (Saint Quentin Fallavier, France). The
caspasesubstratesandthecaspaseinhibitorswerefromMERCKEurolab(Fontenay-
sous-Bois, France). Trypan blue, Dulbecco’s Modiﬁed Eagle’s Medium (DMEM),
penicillin/streptomycin and trypsin were from Invitrogen (Pontoise, France) and, fetal
calf serum (FCS) from Hyclone (Brevieres, France). p21, p27, beclin1, HSP60
antibodies were purchased from Santa Cruz Biotechnology (TEBU; Le Perray en
Yvelines, France). Anti-LC3-b, ATG5, AMPKa (T172), mTOR (S2448), S6 ribosomal
(S235/236) and PARP, AMPKa, mTOR, S6 ribosomal antibodies were from Cell
Signaling (Berverly, MA, USA). Antibodies against cyclin D1 and pRb were from BD
Bioscience (Pont de Claix, France).
Cell cultures. Normal human melanocytes were prepared and maintained as
described.
36 Different melanoma cell lines were purchased from American Tissue
CultureCollection(Molsheim,France).CellsweregrowninRPMI1640(A375,WM9
and SKMel28) or in DMEM medium (G361 and B16) supplemented with 10% FCS
and penicillin/streptomycin (100U/ml/50mg/ml) at 371C and 5% CO2. Patient
melanoma cells were prepared as described.
37 Brieﬂy, biopsy was dissected and
digested for 1–2h with collagenase A (0.33U/ml), dispase (0.85U/ml) and Dnase I
(144U/ml) with rapid shaking at 371C. Large debris were removed by ﬁltration
through a 70-mm cell strainer. Viable cells were obtained by Ficoll gradient
centrifugation.
For each experiment, cells were starved with or without 1% SVF in appropriate
medium during 14h before drug stimulation.
Immunoﬂuorescence microscopy. Monolayers prepared for ﬂuorescent
staining were grown on glass coverslips. Immunoﬂuorescence experiments were
carried out as described.
38
Electron microscopy. Electron microscopy experiments were performed as
described.
39
Caspase activity. Caspase activities were performed as described.
38
Western blot assays. Western blot analyses were performed as described.
40
Quantiﬁcations were made using Fuji Film Multi Gauge software.
Flowcytometryanalysis. All ﬂow cytometryanalyses were performed using
the FL2 channels of a FACScan (Becton Dickinson, Cowley, UK) and data were
analyzed with CellQuest software (Becton Dickinson, Cowley, UK) as previously
described.
38 PI staining was performed using Staining Kit (Roche Diagnostics,
Meylan, France) according to the manufacturer’s protocol.
Transfection experiments. Transfections with RFP-LC3 construct were
carried out by using the FuGENE 6 reagent (Roche Applied Sciences, Meylan,
France) according to the manufacturer’s speciﬁcations. Transfection of duplex
siRNAs (50nM) was carried out using Lipofectamine RNAiMAX (Invitrogen) in Opti-
MEM (Invitrogen). The day after the transfection, metformin was added to the
medium and proteins were extracted 96h after the addition of metformin. Stealth
siRNA targeting AMPKa1, AMPKa2, ATG5 and caspase 3 were purchased from
Invitrogen, whereas LC3-b siRNA were from Dharmacon (Lafayette, CO, USA) and
p21siRNAwerefromSantaCruzBiotechnology.Asnonspeciﬁccontrol,ascramble
sequence siRNAs were used.
Cathepsin B activity. Cathepsin B activity was determined as described.
41
In vivo murine cancer model. Animal experiments were carried out in
accordance with the Declaration of Helsinki and were approved by a local ethical
committee. Female immune-deﬁcient BALB/c nu/nu (nude) mice or female C57/Bl6
mice were obtained at 6 weeks of age from Harlan Laboratory (Gannat, France).
Nude mice or C57/Bl6 mice were inoculated subcutaneously with A375
melanoma cells (2.5 10
6cells/mouse) or B16F10 melanoma murine cells
(2.5 10
5), respectively. After 5 days, animals received intraperitoneal injection
of metformin (2mg/mouse/day) dissolved in PBS. The growth tumor curves were
determined by measuring the tumor volume using the equation V¼(L W2)/2. At
the end of the experiment, mice were euthanized by CO2 inhalation and tumors
were taken for western blot and immunoﬂuorescence experiments. TUNEL assay
was performed using the In Situ Cell Death Detection Kit (Roche, Meylan, France).
Statistical analysis. Data presented are mean ±S.D. of three independent
experiments performed in triplicate. Statistical signiﬁcance was assessed using the
Student’s t-test except for in vivo experiments in which statistical signiﬁcance was
assessed using two-tailed Wilcoxon rank sum test. A value of Po0.05 was
accepted as statistically signiﬁcant.
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